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Information on the distribution and biology of the G-protein coupled receptor 4 (GPR4) in the brain is
limited. It is currently thought that GPR4 couples to Gs proteins and may mediate central respiratory
sensitivity to CO2. Using a knock-in mouse model, abundant GPR4 expression was detected in the ce-
rebrovascular endothelium and neurones of dorsal raphe, retro-trapezoidal nucleus locus coeruleus and
lateral septum. A similar distribution was conﬁrmed using RNAscope in situ hybridisation. In
HEK293 cells, overexpressing GPR4, it was highly constitutively active at neutral pH with little further
increase in cAMP towards acidic pH. The GPR4 antagonist NE 52-QQ57 effectively blocked GPR4-
mediated cAMP accumulation (IC50 26.8 nM in HEK293 cells). In HUVEC which natively express GPR4,
physiological acidiﬁcation (pH 7.4e7.0) resulted in a cAMP increase by ~55% which was completely
prevented by 1 mM NE 52-QQ57. The main extracellular organic acid, L-lactic acid (LL; 1e10mM), sup-
pressed pH dependent activation of GPR4 in HEK293 and HUVEC cells, suggesting allosteric negative
modulation. In unanaesthetised mice and rats, NE 52-QQ57 (20mg kg1) reduced ventilatory response to
5 and 10% CO2. In anaesthetised rats, systemic administration of NE 52-QQ57 (up to 20mg kg1) had no
effect on hemodynamics, cerebral blood ﬂow and blood oxygen level dependent responses. Central
administration of NE 52-QQ57 (1mM) in vagotomised anaesthetised rats did not affect CO2-induced
respiratory responses. Our results indicate that GPR4 is expressed by multiple neuronal populations and
endothelium and that its pH sensitivity is affected by level of expression and LL. NE 52-QQ57 blunts
hypercapnic response to CO2 but this effect is absent under anaesthesia, possibly due to the inhibitory
effect of LL on GPR4.
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
G-protein coupled receptors (GPCR) represent the largest familyand Neuroscience, University
c.uk (A.G. Teschemacher),
nical Sciences, University of
r Ltd. This is an open access articleof drug targets and, for this reason, are widely medically exploited.
Since the publication of the human genome, numerous new puta-
tive GPCRs were identiﬁed, many without any known endogenous
ligands. Such “orphan” GPCR are often still known under the
numbers they were given initially. GPR4 was de-orphanized in
2003 when it was found to be highly sensitive to changes in
extracellular proton concentration (Ludwig et al., 2003). Since that
time, further proton-sensing GPCRs were identiﬁed, namely GPR65
and GPR68 (http://www.guidetopharmacology.org).
The cellular phenotype best established to be associated with
strong GPR4 expression is endothelium in peripheral tissues as well
as in the brain (Huang et al., 2007; Kim et al., 2005; Qiao et al.,
2006; Sun et al., 2016; Wyder et al., 2011), this being consistentunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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GPR4 activity in peripheral endothelial cells has been implicated in
blood vessel formation (Dong et al., 2013), transmigration of
monocytes (Huang et al., 2007), responses to vascular endothelial
growth factor (Wyder et al., 2011), vascular inﬂammation (Dong
et al., 2013) and endothelial adhesiveness (Chen et al., 2011).
Strong GPR4 expression was also shown in the kidney where it
contributes to the control of acid-base balance (Brown andWagner,
2012). However, a recent study (Kumar et al., 2015)/id using in situ
hybridization did not detect GPR4 in the cerebrovascular endo-
thelium but, instead, almost exclusively in neurones of the brain-
stem retrotrapezoid nucleus (RTN), an area known to be important
for central respiratory CO2 chemosensitivity and control of
breathing. At the same time, single cell PCR demonstrated strong
GPR4 expression in the RTN neurones, in the adjacent C1 cate-
cholaminergic neurones (which generate sympathetic tone
(Marina et al., 2013);) and in serotonergic raphe nucleus neurones
(Kumar et al., 2015). That study also found in mice GPR4 deletion
was associatedwith reduced respiratory CO2 sensitivity implicating
GPR4 expressed at RTN neurones in central chemosensitivity to CO2
(Kumar et al., 2015).
Thus, there is a certain controversy regarding localization of
GPR4 in the brain, especially given recent direct demonstration of
GPR4 expression in the capillaries of at least some parts of the brain
(Sun et al., 2016) and images available in Allen brain atlas (http://
www.brain-map.org/).
It is well established that GPR4 is a Gs-coupled receptor which
drives the activity of adenylate cyclase (AC, (Ludwig et al., 2003),
although signaling via G13 and Gq/11 has also been documented
(Tobo et al., 2007). However, the pH-sensitivity proﬁle of GPR4-
mediated cAMP accumulation may have a major effect on the role
of this receptor in the body and brain speciﬁcally. It seems that this
proﬁle may be inﬂuenced by the methods used in different labo-
ratories as it varies between the published reports. Using tran-
siently transfected HEK293 cells (Ludwig et al., 2003), reported that
GPR4 is inactive at pH> 8.0, highly active at physiological pH (7.4)
but further acidiﬁcation to pH 6.8 (which is a plausible range of
physiological acidiﬁcation) only results in a very small further
activation of GPR4. In contrast (Tobo et al., 2007), reported signif-
icant activation of GPR4 in response to acidiﬁcation from 7.4 to 7.0,
which is within the range of physiological pH changes. At the same
time, relatively little is known about pH-dependency of GPR4 in
cells which express it naturally (such as endothelium).
Furthermore, protons which are detected by GPR4 are mainly
derived from either carbonic acid or L-lactic acid (LL). Considering
known signaling properties of LL (Lauritzen et al., 2013; Tang et al.,
2014; Mosienko et al., 2015)we hypothesized that GPR4 could be
additionally modulated by LL. This may have implications for
various scenarios involving acidosis (respiratory vs metabolic).
In this study, we evaluated the CNS expression proﬁle of GPR4
using a cell lineage tracing mouse model, which enables identiﬁ-
cation of cells where the GPR4 locus is activated during ontogeny.
To verify that the expression persists in mature animals we
employed a highly sensitive RNAscope in situ hybridization tech-
nology. We then compared the pH-activation proﬁle of GPR4
expressed using a recombinant approach in HEK293 cells with that
of human vascular endothelium cells (HUVEC) which natively ex-
press GPR4 and tested the hypothesis that GPR4 activity can be
modulated by LL. Next, we studied the pharmacological properties
and physiological effects of a novel GPR4 antagonist, NE 52-QQ57,
developed by Novartis (compound 13 in (Velcicky et al., 2017)). This
molecule is a centrally active GPR4 antagonist, effective after oral
administration. Here, we conﬁrm the high potency of NE 52-QQ57
as a GPR4 blocker and then evaluate its effects on central respira-
tory CO2 chemosensitivity in mice and rats.2. Methods
2.1. Cloning of pCMV-GPR4-hIRES-EGFP
The GPR4 PCR product was obtained from rat genomic DNA and
cloned between BglII and HindIII sites in pCMV-hIRES-EGFP
plasmid to allow bi-cistronic expression of EGFP as a marker of
expression. Sequence of the GPR4 insert was conﬁrmed.
2.2. cAMP measurements in HEK293 cells transiently transfected
with GPR4 and in HUVEC
The GloSensor assay was used for cAMP measurements as pre-
viously described, with modiﬁcations (Binkowski et al., 2011).
Transfection was optimised for the different two cell lines. HEK293
cells were plated in 96-well white polystyrene plates (Greiner Bio-
One) in DMEM media (Gibco) supplemented with 10% FBS and 1%
Penicillin/Streptomycin (Pen/Strep), at a density of 4 105 cells/ml
to achieve ~70% conﬂuence for transfection. After 20 h, cells were
transiently co-transfected with the GloSensor cAMP plasmid
GLO22F and pCMV-GPR4-hIRES-EGFP using Trans-IT 293 (Mirus)
according to the manufacturer's protocol. Transfection efﬁciency
was conﬁrmed by ﬂuorescent visualisation of EGFP. HUVEC were
plated in 96-well white polystyrene plates in endothelial cell
growth medium (Promocell) supplemented with 1% Pen/Strep.
2 104 cells were seeded per well. Since HUVEC are difﬁcult to
transduce using chemical transfectants, we generated an adeno-
viral vector for CMV-driven GLO22F expression and used it with
multiplicity of infection of 75.
26 h after the transfection, cells were incubated with 850mM
beetle luciferin potassium salt (Promega) at pH 7.4 for 2 h in the
dark. Prior to adding drugs, media was changed to HBSS (Gibco)
buffered with 20mM HEPES and titrated to the desired pH. Cells
were incubated with NE 52-QQ57 for 20min in a ﬁnal well volume
of 100ml. Luminescence measurements of cAMP accumulationwere
obtained using a Tecan microplate reader (Inﬁnite M200 PRO).
LL solutions were titrated to neutral pH (7.4) using NaOH and
added to the media, while resultant pH was carefully controlled. A
water soluble forskolin analogue NKH 477 (Santa Cruz Biotech-
nology, 0.1e100mM) was used as a positive control to activate AC in
a receptor-independent manner.
Non-transfected HEK293 cells were unresponsive to pH changes
such as used in these experiments.
2.3. Assessment of the activity of NE 52-QQ57
10mg of NE 52-QQ57 was ﬁrst dissolved in 300ml DMSO and
then further diluted into HBSS as required. In order to assess the
efﬁcacy of NE 52-QQ57 in blocking GPR4-mediated cAMP accu-
mulation, experiments were performed at a range of pH (8.0e6.8).
For estimation of IC50 of NE 52-QQ57, tests were performed at pH
7.4.
2.4. Immunoﬂuorescent localisation of GPR4 in the mouse brain
In order to investigate the pattern of GPR4 expression in the
brain, we generated a lineage tracing mouse model by expressing
CRE recombinase (CreN) from the GPR4 locus. Homologous
recombination of the GPR4-CreN targeting vector was achieved by
transfection of the targeting vector into BALB/c mouse embryonic
stem (ES) cells. Correctly targeted ES cells were selected by PCR and
Southern blot. Targeted BALB/c ES cells were injected into C57Bl/6
host blastocysts and breeding of chimeric mice resulted in GPR4-
CreN mice. These mice were then crossed with a reporter mouse
harboring a ﬂoxed-STOP-EGFP cassette inserted into the Rosa26
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recombination enables reporter expression in cells where CreNwas
present. Description of the GPR4 expression in peripheral tissues in
this animal model is outside of the scope of the present paper.
Male mice (postnatal day 15 or 30) were then deeply anaes-
thetised with isoﬂurane, and transcardially perfused with phos-
phate buffered saline (PBS), followed by 4% paraformaldehyde
(PFA). Brains were removed and ﬁxed in 4% PFA, and then trans-
ferred to 30% sucrose. For further storage, brains were kept in PBS
containing 0.02% sodium azide. Sequential 40mm sections were cut
using a freezing microtome. Prior to antibody staining sections
were incubated with antigen retrieval reagent (Polysciences)
following blocking solution containing 10% goat serum and 0.03%
Triton X-100. Free-ﬂoating sections were stained with antibodies
diluted in PBS containing 1% goat serum and 0.03% Triton X-100.
Anti-GFP (Invitrogen) and anti-TH (Santa Cruz) primary antibodies
were applied in concentration of 1:400 and 1:50 respectively. For
immunoﬂuorescence, Alexa-488 and Alexa-594 (Thermo Fisher
Scientiﬁc) secondary antibodies were used as recommended by the
manufacturer. Fluorescent sections were cover slipped in Vector-
shield™, and GPR4 expression throughout the brain was assessed
using a confocal microscope (Leica SP5).
2.5. Fluorescent in situ hybridization (RNAscope) of GPR4 transcript
in the mouse brain
A nine week old C57BL/6J mouse was euthanized by pentobar-
bital and immediately transcardially perfused with PBS, followed
by 4% PFA. The brain was postﬁxed in 4% PFA overnight at 8 C,
followed by cryoprotection in 20% Sucrose PBS at 8 C for 24 h (all
solutions RNAse free). Brain tissue was then embedded in O.C.T.
matrix, and stored at 80 C until sectioning. 15mm Coronal sec-
tions were cut using a cryostat and mounted on superfrost plus
microscope slides. Mounted sections were used for ﬂuorescence in
situ hybridization (FISH) using RNAscope multiplex ﬂuorescent
assay (Advanced Cell Diagnostics) according to manufacturer in-
structions. Fluorescent sections were cover slipped in Invitrogen
ProlongTM Gold antifade reagent (Thermo Fischer Scientiﬁc). GPR4
transcript localization was assessed using a confocal microscope
(Leica SP5).
2.6. Evaluation of NE 52-QQ57 effects in vivo
All the experiments in the UK were performed in accordance
with the European Commission Directive 2010/63/EU (European
Convention for the Protection of Vertebrate Animals used for
Experimental and Other Scientiﬁc Purposes) and the UK Home
Ofﬁce (Scientiﬁc Procedures) Act (1986) with project approval from
the Institutional Animal Care and Use Committees. Animal
handling at Novartis was performed in accordance with animal
protocols approved by the Kantonales Veterin€aramt Basel (License
number 2586/2015).
2.6.1. Whole body plethysmography in rats and mice
Respiratory rate (RR, breaths min1) and tidal volume (VT, a.u)
were measured by whole-body plethysmography in 10 male C57Bl/
6J mice (Charles River, UK), 20e27g and 8male Sprage-Dawley rats,
98e112g, (UCL Biological Services colony). In brief, animals were
placed in a Plexiglas recording chamber (volume 400ml for mice or
1l for rats) that was slightly pressurised by a continuous inﬂow of
humidiﬁed room air (~1 L min-1). All experiments were performed
at room temperature (22e24 C). The animals were allowed
~15min to acclimatise to the chamber environment at normoxia/
normocapnia (21% O2, 79% N2, and <0.3% CO2). Normoxic hyper-
capniawas induced by switching to a pre-mixed gas containing 21%O2 with 5 or 10% CO2 and the balance made up by N2. The hyper-
capnic mixtures were applied for 5min in succession. The mea-
surements of RR and VT were taken during the last 2min before
exposure to hypercapnia and the last 2min of each hypercapnic
episode, when breathing stabilised. Hypercapnia-induced changes
in the RR, VT, and minute ventilation (VE) (RR VT) were averaged
and expressed as mean± SEM. Each animal underwent recordings
with vehicle (25% v/v DMSO in 0.9% Saline; 200ml per mouse or 1ml
per rat, i.p) and drug (NE-5-0057; 20mg kg-1, i.p) which were
injected immediately before introduction into the plethysmog-
raphy chamber, thus allowing at least 15min for the effect to
develop.
2.6.2. Surgical procedures in rats
Male Wistar rats, 8e9 weeks of age, were anaesthetised (in-
duction 5% isoﬂurane, maintenance a-chloralose 75mg kg1, i.v.)
and instrumented for blood pressure recording via femoral artery
cannulation. The femoral veinwas cannulated for administration of
anaesthetic. The depth of anaesthesia was monitored by the sta-
bility of blood pressure and heart rate. The trachea was cannulated
low in the neckwith a 12 gauge cannula tomaintain airway patency
and/or for mechanical ventilation. Arterial blood gases were
monitored using a blood gas analyser (Model 380EX, Siemens,
Dortmund, Germany) and maintained at PO2 ~120mmHg, PCO2
35e40mmHg, and pH at 7.35e7.45. Body temperature was main-
tained at 37.0± 0.5 C. At the end of the experiments, the animals
were humanely killed by an overdose of pentobarbitone sodium
(200mg kg1, i.v.).
2.6.3. Evaluation of the effects of NE 52-QQ57 on neurovascular
coupling in rats
The rat head was secured within the fMRI scanner with ear and
incisor bars, after which mechanical ventilation was started with
oxygen-enriched air using an MRI compatible ventilator (CWE).
Neuromuscular blockade was induced by gallamine (10mg kg1;
i.v.) and supplemented as necessary. Imaging was performed using
a 9.4T Agilent horizontal bore scanner (Agilent). A 72mm inner
diameter volume coil was used for transmission (Rapid Biomedical)
and signal was received using a 4-channel array head coil (Rapid
Biomedical). A ﬂow sensitive alternating inversion recovery (FAIR)
arterial spin labelling (ASL) MRI sequence was applied with a single
shot gradient-echo echo planar imaging readout for simultaneous
capture of cerebral blood ﬂow (CBF) and T2* weighted blood oxy-
gen level dependent (BOLD) data as described previously (Wells
et al., 2015). The following sequence parameters were used:
TR¼ 5000ms, TI¼ 2000ms, matrix size¼ 64 64, FOV¼ 35mm 
35mm, TE¼ 10ms, single slice (slice thickness¼ 2mm), inversion
pulse bandwidth¼ 20,000Hz (Christie et al., 2012). BOLD and CBF
responses in the somatosensory cortex were triggered by electrical
stimulation of the forepaw. FAIR images were continuously ac-
quired for ~6min during a block design consisting of three periods
of 60s “rest” followed by 60s forepaw stimulation (3Hz, 0.3ms pulse
width, 1.5mA). Two baseline BOLD/CBF time-series measurements
were acquired (~12mins total imaging time). NE 52-QQ57
(10e20mg kg1; i.p.) or vehicle (25% DMSO in phosphate buffered
saline; 1.5ml kg1) was then administered and two further BOLD/
CBF time-series measurements were repeated 15min after drug/
vehicle administration. Vehicle injections were without any effects
(data not shown).
Data analysis: fMRI. BOLD signals were taken from the “control”
images following the global inversion pulse. CBF and BOLD time-
series data, before and after drug/vehicle, were extracted from a
manually drawn ROI in the unilateral forepaw region of the so-
matosensory cortex. The ASL CBF time-series data were corrected
for contamination of BOLD effects at the time-points that coincide
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signal is most different between tag and control conditions. For
each animal, the average CBF/BOLD signal before and during fore-
paw stimulation was taken.
To generate spatial maps of signiﬁcant BOLD signal changes to
forepaw stimulation, BOLD images were spatially smoothed
(0.5mm FWHM Gaussian kernel), and ﬁrst level analysis of each
time-series using an on/off regressor derived from the applied
forepaw stimulus paradigm (and convolved with the standard HRF
(SPM)) was applied to generate a statistical map before and after NE
52-QQ57/vehicle administration. In order to visualise the BOLD
activation maps to forepaw stimulation, a minimum threshold of
p< 0.05 with family wise error correction with a cluster size of >5
voxels was chosen.
2.7. Evaluation of cardiorespiratory effects of NE 52-QQ57 in rats
2.7.1. Peripheral application
With animals spontaneously breathing, the tracheal cannula
was connected to an open-circuit gas delivery system that allowed
control of the composition of the inspired gas mixture. Two
stainless steel braided wires (Advent RM, Oxford, UK) were
implanted into the diaphragm to record diaphragmatic EMG. The
signal was ampliﬁed (10,000x), ﬁltered (500e1500Hz), rectiﬁed
and smoothed (p¼ 50ms).
After a 15min stabilization period following the preparative
surgery, the animals were subjected to a hypercapnic challenge:
CO2 concentration in the inspired gas mixture was increased to 10%
for a period of 2min. Following a 15min recovery period, NE 52-
QQ57 was administered (i.p.) at 10min intervals to achieve cu-
mulative doses of 5, 10 and 20mg kg1 10 min after the ﬁnal dose
was given, the hypercapnic challenge was repeated.
2.7.2. Central application
Animals were transferred to a stereotaxic frame in the supine
position. Mechanical ventilation was started using a positive pres-
sure ventilator (Model 683; Harvard Apparatus) with a tidal volume
of ~2ml and a ventilator rate similar to the normal respiratory
frequency (~60 strokes min1). Neuromuscular blockade was
induced by gallamine (10mg kg1; i.v.) and supplemented as
necessary (1e2mg kg h1).
The ventral brainstem surface was exposed as described previ-
ously (Gourine et al., 2005). Brieﬂy, superﬁcial neck musculature
was divided along the midline by blunt dissection and retracted
with 3-0 sutures. The trachea and oesophagus were tied, bisected
rostral to the tracheal cannula and reﬂected rostrally. The longus
capitis muscle was partially excised to expose the occipital bone.
Using a dental drill with a ﬁne round-head bur, the bone was
carefully removed leaving the dura intact. Upon completion of all
surgical preparation the dura was incised and reﬂected laterally to
expose the ventral surface of the brainstem. Constant ﬂow of CSF
covered the brain surface and was wicked away with a small piece
of tissue. Peripheral chemodenervation was performed, with both
vagi and carotid sinus nerves sectioned bilaterally. Activity from the
central cut end of the right phrenic nerve was recorded as an in-
dicator of central respiratory drive. The signal was ampliﬁed
(20,000x), ﬁltered (500e1500Hz), rectiﬁed and smoothed
(p¼ 50ms).
After a 15min stabilization period, the animals were subjected
to a hypercapnic challenge; CO2 concentration in the inspired gas
mixture was increased to 10% for 2min. Following a 15min re-
covery period, the vehicle (10% DMSO in artiﬁcial cerebro-spinal
ﬂuid) was applied directly to the exposed ventral surface of the
brainstem. A second hypercapnic challenge was applied after
10min. This sequence was repeated following the topicalapplication of NE 52-QQ57 (1mM) on the ventral surface of the
brainstem.
2.7.3. Data analysis
Physiological variables were digitized using a Power 1401
interface (CED) and stored on a PC for ofﬂine processing using Spike
2 software (CED). Hypercapnia-induced changes in the respiratory
rate, amplitude of phrenic nerve discharge or diaphragmatic EMG
bursts, and neural minute ventilation (respiratory rate x burst
amplitude) in control conditions, following application of the
vehicle or GPR4 antagonist were compared with 2-way ANOVA. P
values of <0.05 were considered signiﬁcant. Hemodynamic vari-
ables were averaged over 60 s periods for 5min after application of
each dose of the GPR4 antagonist. The effects of GPR4 application
on HR and BP were compared to a control period taken 5min
immediately preceding the injection of the ﬁrst dose. An extra time
point was taken 10min after the application of the largest dose of
NE 52-QQ57.
3. Results
3.1. GPR4 expression in the mouse brain
3.1.1. Immunoﬂuorescence in transgenic mice
Mice in which CRE was knocked into the GPR4 locus were
crossed with a ROSA-EGFP-reporter line to activate the dormant
EGFP expression cassette. ROSA-reporter mice are considered to be
the best model for ubiquitous expression in all cell types upon
activation and have been extensively used for that purpose (Abe
et al., 2013; Srinivas et al., 2001). Expression of the activate re-
porter EGFP was analysed throughout the whole brain using anti-
GFP immunohistochemistry. It is acknowledged that the activa-
tion of the dormant EGFP transgene could occur at different stages
of animal development, including the embryonic phase. Immuno-
histochemistry revealed very strong marker expression in cerebral
blood vessels of all calibres with signal originating from the
endothelial cells (Fig. 1A). The most prominent expression in non-
vascular cells was detected in the dorsal raphe nucleus (Fig. 1B)
and lateral septum (Fig. 1C-E). EGFP expression was also evident in
area A6 (locus coeruleus), however, only a few EGFP-expressing
neurones were found to be TH-positive, i.e. noradrenergic
(Fig. 1F). Marker expression was undetectable in the C1 adrenergic
cell group. Neuronal labelling was also detected in the RTN as re-
ported previously (Kumar et al., 2015) (Fig. 1G and H). As expected,
GPR4-positive neurones in the RTN were TH-negative (Fig. 1H).
However, these neurones were scarce and had much lower level of
marker expression compared to the neighbouring endothelial cells
or raphe nucleus neurones (Compare Fig. 1 panels G,H with B and
C).
Apart from these distinct nuclei, isolated EGFP-positive neuro-
nes were detected sporadically across the whole brain. These
neurones were fairly large (20e35mm in diameter) with long and
extensive processes but could not be identiﬁed as any known
phenotype (Fig. 1I).
3.1.2. RNAscope FISH
RNAscope labelling results in punctate staining which is likely to
reﬂect local foci of mRNA in the cells which express the relevant
gene (Fig. 1J-Q, see also high power images in the Supplement).
Green puncta were detected in the same areas as in the knock-in
mouse indicating that in a postnatal mouse neuronal expression
persists in multiple locations, including RTN, raphe and lateral
septum. Even though localisation of endothelium was rather difﬁ-
cult in the absence of an additional endothelial stain, on a number
of images vascular structures were also clearly seen (green arrows
Fig. 1. GPR4 expression in the mouse brain.
A-I. Fluorescent immunohistochemistry of GPR4-CRE-STOP-EGFP mouse brain slices using antibodies against EGFP (anti-GFP) and TH (marker of catecholaminergic neurones).
Unless indicated otherwise, scale bars are 50mm.
A. GPR4 expression in blood vessels was prominent throughout the whole brain (see all panels).
B. Strong and wide-spread GPR4 expression in dorsal raphe nucleus neurones.C. GPR4 expression in neurones of the lateral septum.
D, E. Higher magniﬁcation images from areas indicated in panel C.
F. In the locus coeruleus (A6 cell group) GPR4 expression was detected in neurones, some of which were TH-positive (yellow arrows) or TH-negative (white arrows).
G. Ventral edge of the medulla oblongata at the level of RTN. A few RTN neurones could be detected in some sections. Less than 10 EGFP-positive cells per animal were found.
H. Some of the sections at RTN level were double-stained for TH, but TH-positive cells were EGFP-negative and probably belonged to the C1 cell group.
I. Scattered neurones of unclear phenotype were sporadically detected throughout the whole brain.
J-Q e Results of RNAscope FISH.
J. A blood vessel, scale bar 10mm
K. Dorsal raphe
L. lateral septum
M. Lateral septum, magniﬁed from L, scale bar 10mm
N. Locus cortuleus, boundaries highlighted by the dotted line
O. C1 cell group
P and Q: RTN
Green arrows in N and Q e blood vessels
aq e aqueduct; CC e corpus collosum; RTN e retrotrapezoid nucleus
See Supplement for the large scale versions of some of the images.
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qualitatively similar to that observed in the knock-in mouse.
3.2. Comparison of GPR4-mediated cAMP accumulation in
transiently transfected HEK293 cells and in HUVEC which express
GPR4 natively
We initially veriﬁed that receptor-independent cAMP produc-
tion triggered by the soluble forskolin analogue NKH 477 is pH
independent within the physiologically relevant range (pH
8.0e6.8). As shown in Fig. 2A, 20 mM NKH 477 evoked similar ef-
fects across this pH range indicating that the assay was stable
across the pH range, and that other factors, for example AC or
phosphodiesterase activities, did not change signiﬁcantly. Cell lines
transfected with plasmids bearing strong promoters express
transgenes at high level untypical for GPCR. Naïve HEK 293 cells do
not respond to acidiﬁcationwith changes in cAMP (data not shown)
consistent with the lack of GPR4 expression in this cell line (Atwood
et al., 2011). We ﬁrst expressed recombinant GPR4 from the rat
using plasmids with a CMV promoter and found that acidiﬁcation
resulted in a robust increase in cAMP level (Fig. 2B). StrongFig. 2. In vitro characterisation of GPR4 activity.
A. Increases in cAMP induced by a water-soluble forskolin analogue NKH 477 and detected u
477 was applied to naïve HEK293 cells (not GPR4 transfected). Data represent mean ± s.e.m (
way ANOVA).
B. pH-dependent cAMP accumulation in GPR4 expressing HEK293 cells depends on the qua
GPR4. Data represent mean± s.e.m. for averages of triplicates (n¼ 7 of triplicates for 0.1 m
activation curve towards the alkaline range. Activation proﬁle with 0.001 mg/ml DNA leads a p
C. cAMP accumulation in HUVEC at different pH. Increase in cAMP without NE 52-QQ57 at p
ANOVA shows p< 0.01)
D. Concentration-response curve for cAMP production evoked using non-selective b-adren
response to a different Gs-coupled GPCR. Isoprenaline activates natively expressed b2 adren
concentration of the drug.activation occurred in the range between pH 8.0 and 7.4, while
further acidiﬁcation resulted in no further increase in cAMP levels.
This proﬁle closely resembles the one in the original report by
(Ludwig et al., 2003) and suggests that GPR4 acts as a constitutive
driver of cAMP production at neutral pH, but makes it hardly
suitable for detection of physiological pH changes (7.4e7.0). Of
note, the level of cAMP accumulation evoked by GPR4 at neutral pH
is comparable to that achievable using 20 mM of NHK 477 (data not
shown).We hypothesised that such a shift of pH sensitivity towards
the alkaline range is a result of the high level of GPR4 expression
which is common when using transient expression and plasmids
with a strong promoter. We therefore tested pH sensitivity of GPR4-
expressing HEK 293 cells using lower concentrations of DNA. As
suspected, using 100 times less DNA shifted pH sensitivity towards
more acidic values, closer to the physiological range (Fig. 2B).
However, it is extremely difﬁcult to tune the level of the re-
combinant receptor expression to match the physiological levels.
Therefore, we next used HUVEC, which express GPR4 natively and
found that in these cells activation occurs mainly between pH 7.7
and 7.1 (Fig. 2C; see Supplement for additional statistical informa-
tion for this and other datasets) which is closer to the feasiblesing Glosensor assay are stable across the physiologically relevant pH range. 20mM NKH
n¼ 4 of triplicates). Differences are not statistically signiﬁcant (repeated measures one-
ntity of DNA used for transfection and by implication on the level of the expression of
g/ml, n¼ 3 of triplicates for 0.01 and 0.001 mg/ml). High levels of expression shifts the
roﬁle which resembles response of HUVEC (see panel 2C) which express GPR4 natively.
H 7.1 and 6.8 is statistically signiﬁcant (n¼ 6 of triplicates, repeated measures one-way
oceptor agonist isoprenaline to illustrate that HUVEC cells can mount a robust cAMP
oceptors in a concentration-dependent manner (n¼ 3 of triplicates). -∞ indicates zero
Fig. 3. NE 52-QQ57 is a novel GPR4 antagonist working in a physiological range of pH.
A. NE 52-QQ57 (formula above the bar chart) inhibits GPR4-mediated cAMP accumulation but its potency depends on proton concentration (pH). Plotted are mean %
changes± s.e.m. (n¼ 5 of triplicates) where % change is calculated as (with drug e baseline)/(baseline x 100) for every triplicate. Inhibition by NE 52-QQ57 becomes less effective as
pH decreases. Signiﬁcant differences are shown by repeated measures one-way ANOVA with Tukey's multiple comparisons post hoc test (** - p < 0.01).
B. Concentration-response curve for NE 52-QQ57 at pH 7.4. Calculated IC50 is 26.8 nM. Data represent mean± s.e.m. of triplicates. Log 10 corresponds to zero concentration of the
drug.
P.S. Hosford et al. / Neuropharmacology 138 (2018) 381e392 387physiological range. At the same time, the potency of this signalling
system in HUVEC appeared to be rather modest, since between pH
7.4 and 7.1 cAMP level only increased by ~50%. For reference, acti-
vation of Gs-coupled b-adrenoceptors with isoprenaline led to
>400% increase in cAMP (Fig. 2D).3.3. NE 52-QQ57 effect on GPR4 in HEK 293 cells is pH dependent
The effect of NE 52-QQ57 on proton-mediated cAMP accumu-
lation in cells over-expressing GPR4 was dependent on pH (Fig. 3A)
and this dependence in the acidic range could be explained by
competition with protons. NE 52-QQ57 (100nM) was maximally
effective at pH 7.7 but approximately equally effective at pH 8.0 and
7.4. At pH 7.1, the potency of NE 52-QQ57was reduced and at pH 6.8
NE 52-QQ57 (100nM)was ineffective. At pH 7.4, NE 52-QQ57 acts as
a highly potent antagonist of GPR4 mediated cAMP accumulation
with IC50 of 26.8nM (Fig. 3B).3.4. LL inhibits GPR4-mediated pH dependent cAMP accumulation
in HEK293 and HUVEC
When LL was applied to GPR4-transfected HEK293 cells
(DNA concentration 0.1 mg/ml) or to HUVECs at a range of pH
values, it concentration-dependently inhibited the cAMP accu-
mulation induced by acidosis (Fig. 4A and B). In HEK293 cells
the effect was signiﬁcant at 10mM LL, but in HUVEC, 1 and 10
of LL signiﬁcantly inhibited the pH responsiveness (Fig. 4B). NE
52-QQ57 (1 mM) antagonised GPR4-mediated responses in
HEK293 cells but its efﬁcacy was reduced at acidic pH (7.1 and
6.8) presumably due to high level of activation of the over-
expressed receptor (Fig. 4A). In HUVECs, 1 mM of NE 52-QQ78
completely blocked GPR4-mediated cAMP responses at all pH
levels tested (Fig. 4B).3.5. Central effects of NE 52-QQ57 on CO2-induced respiratory
responses in unanaesthetised mice and rats
Minute ventilation (VE) which is the cumulative of RR and VT
was not signiﬁcantly affected at baseline by 20mg kg1 of NE-52-
QQ57 in either rats (n¼ 8) or mice (n¼ 10). Relative to the
vehicle (25% DMSO), NE-52-QQ57 signiﬁcantly attenuated VE dur-
ing hypercapnia at 5 and 10% CO2 in both species. For example, with
10% CO2 VE increased to 216± 11 a.u. in the group treated with
vehicle, but only to 164± 18 a.u. in mice treated with NE-52-QQ57
(p< 0.001). Similarly, in rats at 10% CO2 VE increased to 662 ± 40 a.u.
in the vehicle group, but to 568± 22 a.u. in the treated group
(p< 0.001). Thus, in freely behaving mice and rats NE22-QQ57
blunted hypercapnic response to CO2.
3.6. Evaluation of NE 52-QQ57 cardio-respiratory effects in
anaesthetised rats
In anaesthetised rats, hypercapnia (10% CO2 in the inspired air)
increased respiratory rate from 77± 9 to 94± 13 bursts/min
(Fig. 6A), and this was not affected following systemic adminis-
tration of NE 52-QQ57 (20mg kg1; n¼ 8, 76± 9 to 95± 12 bursts
min1; p¼ 0.92). NE 52-QQ57 had no effect on CO2-evoked in-
creases in diaphragm EMG amplitude (0.25± 0.03 to 0.33± 0.04V
cf. 0.25± 0.02 to 0.34± 0.03V; p¼ 0.94) and minute ventilation
(19± 3 to 32±7A.U cf. 20± 3 to 33±6A.U; p¼ 0.88). Systemic NE 52-
QQ57 also had no effect on basal respiratory rate (Fig. 6B). To
additionally ensure that NE 52-QQ57 reaches the central GPR4
targets, the drug was then delivered directly on the ventral surface
of the brainstem, where the RTN is located. Hypercapnia (10% CO2
in the inspired air) in 7 animals with denervated peripheral che-
moreceptors increased respiratory frequency, phrenic nerve
amplitude and minute ventilation (Fig. 6C). Hypercapnia increased
the respiratory rate from 18± 6 to 40± 5 bursts min1 following
application of the vehicle on the ventral brainstem surface. CO2 had
Fig. 4. LL inhibits cAMP accumulation induced by acidosis in a concentration-dependent manner in (A) HEK293 and (B) HUVEC cells.
All values are normalised to control at pH 8.0 for each triplicate measurement. Two-way repeated measures ANOVA revealed a signiﬁcant effect of pH (p< 0.0001) and LL (p< 0.05)
on cAMP levels in HEK293 cells. Post-hoc Sidak's multiple comparisons test shows conﬁrmed signiﬁcant differences between effects of 0 and 10mM LL (p< 0.05 at pH 7.4 and 6.8,
p< 0.01 at pH 7.1) and between 100 mM and 10mM (p< 0.05), but the difference between 1 and 10mM LL was not signiﬁcant (p¼ 0.53 at pH 7.1, p¼ 0.78 at pH 6.8). In HUVECs, the
same analysis revealed a signiﬁcant effect of pH (p< 0.0001) and LL (p < 0.05) and a signiﬁcant interaction effect (p< 0.001). The post-hoc test shows signiﬁcant differences between
0 and 10mM (p< 0.05 at pH 7.1, p< 0.0001 at pH 6.8), between 100 mM and 10mM (p< 0.05 at pH 7.1, p< 0.0001 at pH 6.8), and between 100 mM and 1mM (p< 0.05 at pH
6.8).n¼ 4e5 of triplicates for each data point in (A) and (B), apart from n¼ 3 for 1mM NE 52-QQ57 curve in HUVEC. 1mM NE 52-QQ57 antagonises pH dependent activation of GPR4,
the block is overcome at acidic pH in HEK293 cells.
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ventral brainstem surface (18± 4 to 41± 5 bursts min1; p¼ 0.86,
Fig. 6C). NE 52-QQ57 had no effect on other components of the
hypercapnic respiratory response including increases in phrenic
nerve burst amplitude (0.04 ± 0.01 to 0.06± 0.02V vs. 0.04 ± 0.02 to
0.06 ± 0.02V; p¼ 0.92) and minute ventilation (11± 4 to 34±8A.U
vs. 11± 2 to 33±7A.U; p¼ 0.97). Direct application of NE 52-QQ57
to the ventral medulla had no effect on baseline respiratory activity
(Fig. 6D).
3.7. Evaluation of the NE 52-QQ57 effects on hemodynamics and
neurovascular coupling
Systemic administration of NE 52-QQ57 (up to 20mg kg1 i.p.,
n¼ 7) did not affect heart rate and blood pressure in anaesthetised
rats (Supplementary Fig. 1). Neither did the drug affect CBF and
BOLD response to somatosensory stimulation (electrical stimula-
tion of the forepaw). There were no differences in the spatial extent
and magnitude of the evoked BOLD signals.
4. Discussion
We have investigated the signalling properties, CNS distribution
and physiological role of GPR4 in the mechanisms of cardiorespi-
ratory control. Previous work had established that, in peripheral
tissues, GPR4 is prominently expressed in the endothelium of blood
vessels (Huang et al., 2007; Kim et al., 2005; Qiao et al., 2006;
Wyder et al., 2011), where its deletion can cause major abnormal-
ities (Yang et al., 2007). In the brain, presence of GPR4 was
conﬁrmed for vascular endothelium (Sun et al., 2016). In addition,
transcriptome data unequivocally map GPR4 to endothelium with
hardly any expression in other brain cell types, at least in front brain
regions (Zhang et al., 2014, 2016). Surprisingly, a recent study re-
ported no GPR4 expression in the CNS blood vessels using in situ
hybridisation. Instead single cell PCR detected GPR4 in neurones of
a few key brainstem nuclei including the RTN (91% GPR4-positive
neurones), catecholaminergic area C1 (83%) and serotonergic
raphe nucleus (100%) (Kumar et al., 2015). Here we employed a
GPR4-CRE reporter knock-in mouse where expression of CRE is
driven by the endogenous locus of the GPR4 gene and leads to theexpression of CRE in all cells in which GPR4 is expressed during
ontogeny, allowing cell lineage tracing by crossing these mice with
a reporter line where expression of EGFP can be induced by CRE.
Given that CRE is driven by the endogenous locus of the GPR4, it is
assumed that it obeys strictly the same rules as the actual transcript
encoded by this locus. We found that the EGFP was highly and
abundantly expressed in all types of cerebral blood vessels (Fig. 1A
and B,C,F,G,H). Labelled vascular cells were found to be mainly (if
not exclusively) endotheliocytes, because the expression can be
traced all theway down to the capillary level and up thewalls of the
larger vessels (arterioles and veins). In addition, prominent EGFP
expression was also found in neurones of the dorsal raphe nuclei
(Fig. 1B) this is consistent with the serotonergic phenotype
expressing GPR4 according to (Kumar et al., 2015). Another area of
strikingly high marker expression is the lateral septum (Fig. 1C)
which was never reported before. The GPR4-CRE reporter approach
leaves room for potential overestimation of the spread of the gene
of interest because expression of GPR4-CRE and CRE-dependent
activation of the reporter gene may occur during early stages of
development, while in the adult the GPR4 locus could be repressed
in some of these cells. Therefore, we employed the recently intro-
duced FISH technique and have obtained comparable results.
RNAscope detection is extremely sensitive and the staining appears
as puncta localised within the cell, rather than an evenly spread
ﬂuorescence (Fig.1J-Q). FISH conﬁrmed GPR4 expression by various
neuronal populations around the brain, including RTN, raphe, A6
group (locus coeruleus) and lateral septum. Since these results
were obtained from amaturemouse, they conﬁrm that our ﬁndings
in the knock-in model were not a result of embryonic activation of
the GPR4 locus. Expression in endothelium could also be detected,
although without counter-staining (which we could not perform),
the blood vessels could only be identiﬁed by their shape. Admit-
tedly, the density of FISH signal in the endothelium was less than
we expected from the lineage tracing study, suggesting some
reduction in GPR4 level in the endothelium in the mature animals.
Interestingly, both, raphe nucleus (Balaban, 2002; Deakin, 1991;
Graeff et al., 1996; Mosienko et al., 2012) and lateral septum (Albert
and Walsh, 1982; Talishinsky and Rosen, 2012; Yadin et al., 1993)
have been extensively implicated in control of anxiety and
aggression. Our study justiﬁes further exploration of potential role
Fig. 5. NE 52-QQ57 blunts hypercapnic response to 5% and 10% CO2 in unanaesthetised mice (n¼10) and rats (n¼8).
VT and VE measured at 5 and 10% CO2 were signiﬁcantly reduced by NE 52-QQ57 (20mg kg1 i.p.) relative to the vehicle group (25% DMSO).**p < 0.01 and ****p < 0.0001 vs. vehicle,
repeated measurement two-way ANOVA followed by Sidak's multiple comparisons test.
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animals can be conﬁrmed at protein level. It also points to the very
likely role of GPR4 in regulation of brain endothelial function and
signalling between endothelium and parenchyma which we
postulated earlier (Paton et al., 2002).
The pioneering study which for the ﬁrst time established GPR4
as a proton sensitive receptor (Ludwig et al., 2003)reported that the
intracellular coupling for this receptor occurs via AC and that its
activation occurs mainly between alkaline (~8.0) and neutral (~7.3)
pH. This “ﬂat” proﬁle in the physiological pH range (7.4e7.0) was
also documented by (Tobo et al., 2007) making it difﬁcult to
envisage this receptor as a primary pH sensor in the brainstem,
where pH is rather tightly controlled and kept within ~7.6e7.0. In
this study we re-evaluated GPR4-mediated proton-activated cAMP
production in two model cell systems: HEK293 cells transiently
transfected to overexpress GPR4, and HUVEC cells which express
GPR4 natively. We ﬁrst conﬁrmed that the assay is sufﬁciently
stable across the relevant pH range, this being necessary in light of
previous reports of pH sensitive species of AC (Anand-Srivastava
and Johnson, 1980; Birnbaumer and Yang, 1974). In HEK293 cells,
transfected with recombinant GPR4 (but not naïve HEK293), cAMP
accumulation occurred in the alkaline range, between pH 8.0 and
7.4 (Fig. 2B) with no further cAMP increase at acidic pH (6.8). Thisoperational range would be hardly suitable for CO2 monitoring in
the brain. In contrast, HUVEC cells had a radically different activa-
tion proﬁle (Fig. 2C) whereby essentially all GPR4-mediated cAMP
accumulation occurred between pH 7.4 and 7.1. This range com-
pares well to previous ﬁndings in HUVEC (Wyder et al., 2011). We
hypothesised that the alkaline-shifted operational range of GPR4 in
HEK293 cells registered here and in several previous studies could
be explained by the high receptor expression levels typical for
transient expression experiments in cell lines. Indeed, by lowering
concentration of the GPR4 expressing plasmid we obtained a pro-
ﬁle which better resembled the activation curve in HUVEC (Fig. 2B
and C).
Therefore, as illustrated in Fig. 7, relatively high GPR4 levels (as
in overexpressing HEK293 cells) are likely to lead to high GPR4
activity at neutral pH 7.4. In the case of a neurone, this couldmake it
more excitable and active at neutral pH. At the same time, such an
activation proﬁle would be unsuitable for the detection of the
changes in pH within physiologically relevant range (e.g. 7.4 to 6.8).
Lower level of expression (as exempliﬁed by HUVEC) offers a
mechanism for the detection of physiological acidiﬁcation but the
potency of this mechanism seems to be limited. cAMP in HUVEC
only increased by ~50% (Fig. 2C), a rather modest effect when
compared to that of a canonical activator of Gs signalling, the b2
Fig. 6. Peripheral or central administration of NE 52-QQ57 has no effect on CO2-induced respiratory responses.
A. Averaged responses (left) and raw traces (right) to illustrate responses to hypercapnia after i.p. administration of NE 52-QQ57 (20mg kg1). Di e raw activity of the diaphragm, ʃDi
e integrated activity of the diaphragm to illustrate respiration.
B. Effect of i.p. administration of NE 52-QQ57 (20mg kg1) on baseline diaphragmatic EMG activity.
C. Responses to hypercapnia after topical application of NE 52-QQ57 (1mM) on the ventral surface of the medulla oblongata. NE 52-QQ57 had no effect on CO2-induced responses
(two-way ANOVA). PN e activity of the phrenic nerve.
D. Effect of direct application of NE 52-QQ57 (1mM) on the ventral surface of the medulla oblongata on baseline phrenic nerve activity. PN Rate e frequency of respiration measured
from the ʃPN traces.
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be more important for the action of GPR4 (see introduction), this
includes also slow, genomic mechanisms which only become
relevant under chronic conditions, such as during tumour
formation.
Protons which can activate GPR4 are mainly derived from car-
bonic acid and LL, the two key tissue acids. Concentrations of LL in
plasma and brain are highly dynamic, in most reports ranging be-
tween 100 mM and 5mM, and increasing to 10mM under condi-
tions of hypoxia, metabolic stress or severe exercise (MosienkoFig. 7. Schematic to illustrate the putative impact of GPR4 expression level on its func
High level of expression (as exempliﬁed by transiently transfected HEK293 cells) leads to
insensitive to physiological acidiﬁcation. Low, natural level of expression, such as in HUVEC,
the potency of GPR4-mediated signaling via cAMP, making it unsuitable for fast and robuset al., 2015). We found that LL has, irrespective of the action of
protons, an additional effect on GPR4. Both in HEK293 and HUVEC,
LL reduced proton-mediated cAMP accumulation mediated by
GPR4 (Fig. 4). This effect was evident at 1mM and increased
signiﬁcantly with 10mM of LL. We cannot completely exclude the
possibility that high concentrations of LL (e.g. 10mM and above)
might have effects unrelated to the signalling mechanism under
study, for example via LL effects on energy production and/or
mitochondrial redox state. Nevertheless, the data obtained suggest
that LL at biologically relevant concentrations acts as a negativetion.
production of copious amounts of cAMP at neutral pH (7.4) and makes the system
reveals GPR4 mediated responses within the physiological window (7.4e6.8) but limits
t cellular responses.
P.S. Hosford et al. / Neuropharmacology 138 (2018) 381e392 391(possibly allosteric) modulator of GPR4-mediated signalling. The
data also suggest that under physiological blood and brain LL
concentration (usually ~1mM), GPR4 is partially tonically inhibited
by LL and its sensitivity to protons is lower than could be expected
from in vitro assays.
The recently published GPR4 blocker, NE 52-QQ57 (Velcicky
et al., 2017), represents a promising new family of drugs, because
GPR4 is one of the potential targets in cancer therapy (Castellone
et al., 2011; Damaghi et al., 2013) and inﬂammatory responses
(Chen et al., 2011; Dong et al., 2013). Our experiments conﬁrm NE
52-QQ57 as a highly potent but pH-dependent inhibitor of GPR4-
mediated cAMP accumulation with an IC50 of 26.8 nM at physio-
logical pH (7.4) in HEK293 cells. It was less effective under acidic
(pH 7.1e6.8) or alkaline (pH 8) conditions but 1 mM of NE 52-QQ57
completely abrogated any pH dependent cAMP responses in
HUVEC. However, clinical application of GPR4 blockers would be
problematic if these drugs had serious adverse effects on cardio-
vascular and/or respiratory homeostasis.
We investigated this issue in awake mice and rats. In unan-
aesthetised animals 20mg kg1 of NE 52-QQ57 caused a small, but
signiﬁcant reduction in the ventilatory response to hypercapnia
evoked by 5 and 10% CO2. This effect is consistent with the
phenotype of GPR4 knock-out mice (Kumar et al., 2015). With
reference to the in vitro parts of our study, the ﬁndings in mice may
be best described by the “low level of expression” scenario (Fig. 7),
whereby GPR4 acts as a weak constitutive driver of cAMP with a
small additional capacity to further elevate cAMP during physio-
logical acidiﬁcation. In anaesthetised rats, systemic peripheral
administration of NE 52-QQ57 in doses of up to 20mg kg1 had no
effect on respiratory CO2 chemosensitivity (Fig. 5), resting arterial
blood pressure and heart rate. Direct application of NE 52-QQ57
onto the ventral surface of the brainstem also did not affect cardio-
respiratory homeostasis (Fig. 6). Neurovascular coupling in the
somatosensory cortex (Supplementary Fig. 1) was also fully
preserved.
One possible reason for the lack of NE 52-QQ57 effect on CO2
sensitivity under anesthesia is the inhibitory action of LL on GPR4
as demonstrated here (Fig. 4). Indeed, some anaesthetics such as
urethane can signiﬁcantly increase LL concentration (Alfaro and
Palacios, 1997), although we were unable to ﬁnd similar evidence
for chloralose which was used here. If, however LL is increased by
the anaesthetic, it could mask the GPR4-mediated effects. At the
same time, we know that the other mechanism of chemosensitivity
which resides in astrocytes is fully functional under chloralose
anaesthesia (Gourine et al., 2010).
Altogether, NE 52-QQ57 has no serious detrimental effects on
cardiovascular and respiratory systems in rodents, and this may be
considered as encouraging news for further development of po-
tential clinical applications of GPR4 antagonists. The recent
demonstration of antinociceptive activity of NE 52-QQ57 highlights
a potential avenue for exploration (Velcicky et al., 2017), as does the
potential application of another GPR4 antagonist for treatment of
myocardial infarction (Fukuda et al., 2016). Further promising ap-
plications involve cancer therapy (Justus et al., 2013; Wyder et al.,
2011; Yang et al., 2007), neuro-inﬂammation, or renal disease.
The biological signiﬁcance of GPR4 expression in multiple neuronal
populations requires further investigation, especially given the
association of some of these nuclei with anxiety and responses to
stress.
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